Asset
Hydrogen peroxide
Aclaris Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03210337 | phase2 | completed | 2017-08-01 | 2018-03-16 | Aclaris Therapeutics, Inc. | A Phase2 of A-101 Topical Solution in Subjects With Common Warts |
| NCT02667275 | phase3 | completed | 2016-01-01 | 2016-10-01 | Aclaris Therapeutics, Inc. | A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis |
| NCT03148691 | phase2 | completed | 2017-05-17 | 2018-02-28 | Aclaris Therapeutics, Inc. | A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis |
| NCT02667236 | phase3 | completed | 2016-01-01 | 2016-10-01 | Aclaris Therapeutics, Inc. | A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. |
| NCT03278028 | phase2 | completed | 2017-07-13 | 2018-03-01 | Aclaris Therapeutics, Inc. | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 209305 | NDA | ACLARIS THERAPEUTICS INC |
Marketed products (1)
- ESKATA